Previous 10 | Next 10 |
2023-05-02 17:11:45 ET Although its Q1 2023 bottom line results came in below expectations, Dynavax Technologies ( NASDAQ: DVAX ) is trading flat in after-hours trading. The boost could be the result of a sigh of relief from investors as the company maintained its 2023 financi...
2023-05-02 16:12:00 ET Dynavax press release ( NASDAQ: DVAX ): Q1 GAAP EPS of -$0.19 misses by $0.06 . Revenue of $46.92M (-58.8% Y/Y) beats by $8.33M . Full year 2023 financial guidance is reiterated and consists of the following expectations: HEPLISAV...
Dynavax Reports First Quarter 2023 Financial Results PR Newswire HEPLISAV-B ® vaccine net product revenue increased 109% year-over-year to $43.5 million in the first quarter of 2023 Reaffirming HEPLISAV-B net product revenue guidance for full...
Dynavax to Report First Quarter 2023 Financial Results and Host Conference Call on May 2, 2023 PR Newswire EMERYVILLE, Calif. , April 18, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company develo...
2023-03-24 06:30:57 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks aren’t for everyone. They require some additional research and as an investor you have to be comfortable having product pipelines with a long pathway to market. Biotec...
Dynavax to Present at the Cowen 43rd Annual Health Care Conference PR Newswire EMERYVILLE, Calif. , March 1, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing...
Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine PR Newswire HEPLISAV B is the only two-dose adult hepatitis B vaccine offering protection in just one month EMERYVILLE, Calif. , Feb....
Image source: The Motley Fool. Dynavax Technologies (NASDAQ: DVAX) Q4 2022 Earnings Call Feb 23, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: Dynavax Technologies (DVAX) Q4 2022 Earnings Call Transcript
Dynavax Technologies Corporation (DVAX) Q4 2022 Results Conference Call February 23, 2023 04:30 PM ET Company Participants Nicole Arndt - Senior Manager, IR Ryan Spencer - CEO Donn Casale - SVP, Commercial Rob Janssen - Chief Medical Officer Kelly MacDonald - C...
Dynavax press release ( NASDAQ: DVAX ): Q4 GAAP EPS of $0.45 in-line. Revenue of $184.49M (-5.4% Y/Y) beats by $6.11M . HEPLISAV-B ® vaccine net product revenue of $126 million, representing 104% growth compared to 2021 CpG 1018 ® adjuvant vaccine net...
News, Short Squeeze, Breakout and More Instantly...
Dynavax Technologies Corporation Company Name:
DVAX Stock Symbol:
NASDAQ Market:
Dynavax Technologies Corporation Website:
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 PR Newswire EMERYVILLE, Calif. , July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company dev...
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program PR Newswire EMERYVILLE, Calif. , June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing inn...
2024-06-21 02:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...